| pubmed-article:17409935 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C1512162 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C2700456 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0079083 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0045093 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0013230 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0203939 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0075616 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0021201 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C2698018 | lld:lifeskim |
| pubmed-article:17409935 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:17409935 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:17409935 | pubmed:dateCreated | 2007-4-5 | lld:pubmed |
| pubmed-article:17409935 | pubmed:abstractText | Carboplatin and gemcitabine are one standard regimen for patients with advanced non-small cell lung cancer (NSCLC). The oral proapoptotic agent exisulind is a cyclic guanosine monophosphate phosphodiesterase that increases apoptosis in vitro. We performed a phase II trial of carboplatin and gemcitabine with exisulind in patients with advanced NSCLC. | lld:pubmed |
| pubmed-article:17409935 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17409935 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17409935 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17409935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17409935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17409935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17409935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17409935 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17409935 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17409935 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17409935 | pubmed:issn | 1556-1380 | lld:pubmed |
| pubmed-article:17409935 | pubmed:author | pubmed-author:JohnsonDavidD | lld:pubmed |
| pubmed-article:17409935 | pubmed:author | pubmed-author:LangerCoreyC | lld:pubmed |
| pubmed-article:17409935 | pubmed:author | pubmed-author:MastersGregor... | lld:pubmed |
| pubmed-article:17409935 | pubmed:author | pubmed-author:DowlatiAfshin... | lld:pubmed |
| pubmed-article:17409935 | pubmed:author | pubmed-author:LiSiguiS | lld:pubmed |
| pubmed-article:17409935 | pubmed:author | pubmed-author:SchillerJoanJ | lld:pubmed |
| pubmed-article:17409935 | pubmed:author | pubmed-author:MadajewiczSte... | lld:pubmed |
| pubmed-article:17409935 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17409935 | pubmed:volume | 1 | lld:pubmed |
| pubmed-article:17409935 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17409935 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17409935 | pubmed:pagination | 673-8 | lld:pubmed |
| pubmed-article:17409935 | pubmed:dateRevised | 2008-5-6 | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:meshHeading | pubmed-meshheading:17409935... | lld:pubmed |
| pubmed-article:17409935 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17409935 | pubmed:articleTitle | A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501). | lld:pubmed |
| pubmed-article:17409935 | pubmed:affiliation | Christiana Care CCOP, Newark, Delaware, USA. | lld:pubmed |
| pubmed-article:17409935 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17409935 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:17409935 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17409935 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17409935 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17409935 | lld:pubmed |
